Phase III randomized trial of gabapentin in patients with amyotrophic lateral sclerosis
- 10 April 2001
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Neurology
- Vol. 56 (7), 843-848
- https://doi.org/10.1212/wnl.56.7.843
Abstract
Background: Preclinical and clinical studies of gabapentin in patients with ALS led the authors to undertake a phase III randomized clinical trial. Methods: Patients were randomly assigned, in a double-blinded fashion, to receive oral gabapentin 3,600 mg or placebo daily for 9 months. The primary outcome measure was the average rate of decline in isometric arm muscle strength for those with two or more evaluations. Results: Two hundred four patients enrolled, 196 had two or more evaluations, and 128 patients completed the study. The mean rate of decline of the arm muscle strength was not significantly different between the groups. Moreover, there was no beneficial effect upon the rate of decline of other secondary measures (vital capacity, survival, ALS functional rating scale, timed walking) nor was there any symptomatic benefit. In fact, analysis of the combined data from the phase II and III trials revealed a significantly more rapid decline of forced vital capacity in patients treated with gabapentin. Conclusion: These data provide no evidence of a beneficial effect of gabapentin on disease progression or symptoms in patients with ALS.Keywords
This publication has 13 references indexed in Scilit:
- Consensus guidelines for the design and implementation of clinical trials in ALSJournal of the Neurological Sciences, 1999
- Practice advisory on the treatment of amyotrophic lateral sclerosis with riluzole: Report of the Quality Standards Subcommittee of the American Academy of Neurology [RETIRED]Neurology, 1997
- Placebo-controlled trial of gabapentin in patients with amyotrophic lateral sclerosisNeurology, 1996
- A double‐blind placebo‐controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rHCNTF) in amyotrophic lateral sclerosisNeurology, 1996
- A clinical trial of verapamil in amyotrophic lateral sclerosisMuscle & Nerve, 1996
- Controlled trial of nimodipine in amyotrophic lateral sclerosisNeuromuscular Disorders, 1996
- A placebo‐controlled trial of recombinant human ciliary neurotrophic (rhCNTF) factor in amyotrophic lateral sclerosisAnnals of Neurology, 1996
- Benefit of vitamin E, riluzole, and gababapentin in a transgenic model of familial amyotrophic lateral sclerosisAnnals of Neurology, 1996
- Treatment of ALS with high dose pulse cyclophosphamideJournal of the Neurological Sciences, 1994
- Quantitative motor assessment in amyotrophic lateral sclerosisNeurology, 1986